Status:
COMPLETED
Dichotic Listening as a Predictor of Medication Response in Depression
Lead Sponsor:
New York State Psychiatric Institute
Conditions:
Major Depressive Disorder
Dysthymia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This study will recruit 100 depressed patients to test whether the previous finding of an association between treatment response (with treatment groups including placebo, imipramine, and fluoxetine) a...
Detailed Description
Preliminary data suggest that depressed patients with increased left hemispheric laterality of perceptual processing are unlikely to improve during 6 weeks' treatment with placebo, while being very re...
Eligibility Criteria
Inclusion
- Ages between 18-65
- Meets Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) criteria for current Major Depression, Dysthymia or Depression Not Otherwise Specified
Exclusion
- Known Hearing impairment
- Active suicidal ideation (history of suicide attempts will be evaluated on a case by case basis).
- Hamilton Rating Scale for Depression (HAMD), 21-item total score \>20
- Current (past 6 months)alcohol and/or drug abuse or dependence
- Medical condition likely to require intervention contraindicated with study medication (e.g., known arrhythmia likely to be exacerbated by Imipramine)
- Bipolar I
- Psychosis
- Non-response to adequate trial of study medication (i.e., \> or = 4 weeks on \> or = bupropion 300mg/d, escitalopram 30mg/d, or imipramine 200mg/d)
- Premenopausal women not using known effective birth control
- Not currently depressed (whether considered due to current treatment or not)
- History of seizure, seizure disorder, anorexia nervosa, or bulimia
- Left-handed -
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00404755
Start Date
July 1 2006
End Date
August 1 2011
Last Update
April 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032